Of the available adjuvants shown to enhance the T-cell responses that are considered critical for protection against leishmaniasis, TLR4 agonists are by far the most advanced and, indeed, are the only TLR agonists in approved vaccines. This evidence concerns the gene TLR4 and leishmaniasis.